Recent advances in the development of vaccines against ricin
Open Access
- 25 January 2016
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 12 (5) , 1196-1201
Abstract
Several promising subunit vaccines against ricin toxin (RT) have been developed during the last decade and are now being tested for safety and immunogenicity in humans and for efficacy in nonhuman primates. The incentive to develop a preventive vaccine as a countermeasure against RT use as a bioweapon is based on the high toxicity of RT after aerosol exposure, its environmental stability, abundance, and ease of purification. RT is the second most lethal biological toxin and is considered a “universal toxin” because it can kill all eukaryotic cells through binding to ubiquitous cell surface galactosyl residues. RT has two subunits conjoined by a single disulfide linkage: RTB, which binds galactosyl residues and RTA which enzymatically inactivates ribosomes intracellularly by cleavage ribosomal RNA. Attenuation of toxicity by elimination of the active site or introduction of other structural mutations of RTA has generated two similar clinical subunit vaccine candidates which induce antibodies in both humans and nonhuman primates. In rhesus macaques, inhaled RT causes rapid lung necrosis and fibrosis followed by death. After parenteral vaccination with RTA vaccine, macaques can be protected against aerosol RT exposure, suggesting that circulating antibodies can protect lung mucosa. Vaccination induces RT-neutralizing antibodies, the most likely correlate of protection. Macaques responded to conformational determinants in an RTA vaccine formulation, indicating preservation of RTA structure during initial manufacture. Comparative mapping studies have also demonstrated that macaques and humans recognize the same epitopes, significant in the study of macaques as a model during development of vaccines which cannot be tested for efficacy in humans.Keywords
This publication has 44 references indexed in Scilit:
- Antibody to Ricin A Chain Hinders Intracellular Routing of Toxin and Protects Cells Even after Toxin Has Been InternalizedPLOS ONE, 2013
- Pilot Phase IB Clinical Trial of an Alhydrogel-Adsorbed Recombinant Ricin VaccineClinical and Vaccine Immunology, 2012
- Structure of RiVax: a recombinant ricin vaccineActa Crystallographica Section D Structural Biology, 2011
- Folding domains within the ricin toxin A subunit as targets of protective antibodiesVaccine, 2010
- Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxicationVaccine, 2010
- A Monoclonal Immunoglobulin G Antibody Directed against an Immunodominant Linear Epitope on the Ricin A Chain Confers Systemic and Mucosal Immunity to RicinInfection and Immunity, 2010
- Vaccines: Correlates of Vaccine‐Induced ImmunityClinical Infectious Diseases, 2008
- RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosolVaccine, 2007
- Intrapulmonary Delivery of Ricin at High Dosage Triggers a Systemic Inflammatory Response and Glomerular DamageThe American Journal of Pathology, 2007
- A novel recombinant vaccine which protects mice against ricin intoxicationVaccine, 2002